HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

HLA class II molecule HLA-DRA identifies immuno-hot tumors and predicts the therapeutic response to anti-PD-1 immunotherapy in NSCLC

Abstract Background Immune checkpoint blockade (ICB) only works well for a certain subset of patients with non-small cell lung cancer (NSCLC). Therefore, biomarkers for patient stratification are desired, which can suggest the most beneficial treatment. Methods In this study, three datasets (GSE1260...

Full description

Bibliographic Details
Main Authors: Jie Mei, Guanyu Jiang, Yundi Chen, Yongrui Xu, Yuan Wan, Ruo Chen, Feng Liu, Wenjun Mao, Mingfeng Zheng, Junying Xu
Format: Article
Language:English
Published: BMC 2022-07-01
Series:BMC Cancer
Subjects:
NSCLC
Immunotherapy
PD-1
HLA-DRA
Bioinformatics
Online Access:https://doi.org/10.1186/s12885-022-09840-6

Internet

https://doi.org/10.1186/s12885-022-09840-6

Similar Items